1. Barik, Ganesh Kumar, Sahay, Osheen, Mukhopadhyay, Anindya, Nath, Somsubhra, Santra, Manas Kumar. 2023. FBXW2 suppresses breast tumorigenesis by targeting AKT-Moesin-SKP2 axis. In Cell death & disease, 14, 623. doi:10.1038/s41419-023-06127-x. https://pubmed.ncbi.nlm.nih.gov/37736741/
2. Wang, Cheng, Xu, Wenjing, Chao, Yuelin, Zhang, Fengxiao, Huang, Kai. 2020. E3 Ligase FBXW2 Is a New Therapeutic Target in Obesity and Atherosclerosis. In Advanced science (Weinheim, Baden-Wurttemberg, Germany), 7, 2001800. doi:10.1002/advs.202001800. https://pubmed.ncbi.nlm.nih.gov/33101872/
3. Yin, Yuan, Xie, Chuan-Ming, Li, Hua, Xiong, Xiufang, Sun, Yi. 2019. The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells. In Proceedings of the National Academy of Sciences of the United States of America, 116, 20528-20538. doi:10.1073/pnas.1905973116. https://pubmed.ncbi.nlm.nih.gov/31548378/
4. Yang, Fei, Xu, Jie, Li, Hua, Xiong, Xiufang, Sun, Yi. 2019. FBXW2 suppresses migration and invasion of lung cancer cells via promoting β-catenin ubiquitylation and degradation. In Nature communications, 10, 1382. doi:10.1038/s41467-019-09289-5. https://pubmed.ncbi.nlm.nih.gov/30918250/
5. Xu, Jie, Zhou, Weihua, Yang, Fei, Xiong, Xiufang, Sun, Yi. 2017. The β-TrCP-FBXW2-SKP2 axis regulates lung cancer cell growth with FBXW2 acting as a tumour suppressor. In Nature communications, 8, 14002. doi:10.1038/ncomms14002. https://pubmed.ncbi.nlm.nih.gov/28090088/
6. Xia, Shunjie, Ji, Lin, Tao, Liye, Xu, Junjie, Cai, Xiujun. 2021. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance. In Cellular and molecular gastroenterology and hepatology, 12, 1121-1143. doi:10.1016/j.jcmgh.2021.04.016. https://pubmed.ncbi.nlm.nih.gov/33962073/
智鼠故事 
